Combinational treatment may prove to be less efficient, as the inhibition of AT1R and Ang II production at the same time increases the bradykinin production – which promotes cancer growth – inhibiting the Ang II/AT2R-mediated tumour suppression effect and allowing renin production, which promotes Ang II-independent growth signalling pathways. The gene discussed is AGT; the disease is neoplasm.